Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603
Cited by 1
Related Papers
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
|Journal of Biological Chemistry|2011|441
Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold
|Journal of Medicinal Chemistry|2011|223
Structure-Based Approach for the Discovery of Pyrrolo[3,2-<i>d</i>]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
|ACS Medicinal Chemistry Letters|2012|171
Studies on Disease-Modifying Antirheumatic Drugs: Synthesis of Novel Quinoline and Quinazoline Derivatives and Their Anti-inflammatory Effect
|Journal of Medicinal Chemistry|1996|151
Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors
|Bioorganic & Medicinal Chemistry|2013|79